(PubMed) Choi HK, Gao X, Curhan G
Certified sterile manufacturing Flexible packaging & private label options Exporting to 30+ countries worldwide Contact us today for quotations, dossiers, or sample requests.
GLP-1 therapies influence pathways tied to addiction and reward, according to the Endocrine Society A randomized clinical trial published in JAMA Psychiatry found semaglutide reduced alcohol cravings and consumption Users commonly report: Reduced desire to drink Feeling full faster when drinking Less reward from alcohol The data: early, but directionally consistent While long-term industry sales data is still developing, the early signals from clinical studies, observational research, and population polling all point in the same direction: GLP-1 use is associated with lower alcohol consumption for at least some users
It sounds like someone who's really done their research
Additionally, HSDD is associated with broader health concerns like depression, sleep disturbances, and lowered life quality, with research showing women with HSDD report 20-30% higher distress levels.[5][8] It's a cycle: low desire leads to avoidance, which reinforces the problem, underscoring why addressing it early is key